# Lapatinib Ditosylate and Capecitabine in Treating Patients With Stage IV Breast Cancer and Brain Metastases

> **NCT00967031** · PHASE2 · COMPLETED · sponsor: **UNICANCER** · enrollment: 45 (actual)

## Conditions studied

- Breast Cancer
- Metastatic Cancer

## Interventions

- **DRUG:** capecitabine
- **DRUG:** lapatinib ditosylate
- **OTHER:** circulating tumor cell analysis
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00967031
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2012-02
- **Final completion:** —
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2013-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00967031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00967031, "Lapatinib Ditosylate and Capecitabine in Treating Patients With Stage IV Breast Cancer and Brain Metastases". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00967031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*